- Home
- NMT vs APLT Comparison
NMT vs APLT Comparison
Compare NMT & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- APLT
- Stock Information
- Founded
- NMT 1993
- APLT 2016
- Country
- NMT United States
- APLT United States
- Employees
- NMT N/A
- APLT N/A
- Industry
- NMT Finance/Investors Services
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- NMT Finance
- APLT Health Care
- Exchange
- NMT Nasdaq
- APLT Nasdaq
- Market Cap
- NMT 108.5M
- APLT 128.0M
- IPO Year
- NMT N/A
- APLT 2019
- Fundamental
- Price
- NMT $11.40
- APLT $0.65
- Analyst Decision
- NMT
- APLT Buy
- Analyst Count
- NMT 0
- APLT 7
- Target Price
- NMT N/A
- APLT $6.10
- AVG Volume (30 Days)
- NMT 19.1K
- APLT 7.5M
- Earning Date
- NMT 01-01-0001
- APLT 03-05-2025
- Dividend Yield
- NMT 3.21%
- APLT N/A
- EPS Growth
- NMT N/A
- APLT N/A
- EPS
- NMT N/A
- APLT N/A
- Revenue
- NMT N/A
- APLT N/A
- Revenue This Year
- NMT N/A
- APLT N/A
- Revenue Next Year
- NMT N/A
- APLT $2,622.90
- P/E Ratio
- NMT N/A
- APLT N/A
- Revenue Growth
- NMT N/A
- APLT N/A
- 52 Week Low
- NMT $9.05
- APLT $0.60
- 52 Week High
- NMT $10.93
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- NMT 40.70
- APLT 20.60
- Support Level
- NMT $11.31
- APLT $0.60
- Resistance Level
- NMT $11.60
- APLT $0.74
- Average True Range (ATR)
- NMT 0.15
- APLT 0.09
- MACD
- NMT -0.00
- APLT 0.21
- Stochastic Oscillator
- NMT 57.45
- APLT 13.53
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.